LitAlert ~~

    • Molecular Characterization of BRCA1 c.5339T>C Missense Mutation in DNA Damage Response of Triple-Negative Breast Cancer.
    • Lee JD, Ryu WJ, Han HJ, Kim TY, Kim MH, Sohn J.
    • Cancers (Basel). 2022 May 13;14(10):2405. doi: 10.3390/cancers14102405.
    • Clinical Impact of Pathogenic Variants in DNA Damage Repair Genes beyond BRCA1 and BRCA2 in Breast and Ovarian Cancer Patients.
    • Espinel W, Champine M, Hampel H, Jeter J, Sweet K, Pilarski R, Pearlman R, Shane K, Brock P, Westman JA, Kipnis L, Sotelo J, Chittenden A, Culver S, Stopfer JE, Schneider KA, Sacca R, Koeller DR, Gaonkar S, Vaccari E, Kane S, Michalski ST, Yang S, Nielsen SM, Bristow SL, Lincoln SE, Nussbaum RL, Esplin ED.
    • Cancers (Basel). 2022 May 13;14(10):2426. doi: 10.3390/cancers14102426.
    • Do Female BRCA2 Pathogenic Variant Carriers Have an Increased Risk of Lung Cancer?
    • Fallet V, Sanchis-Borja M, Benusiglio PR, Cadranel J.
    • J Clin Oncol. 2022 May 12:JCO2200488. doi: 10.1200/JCO.22.00488. Epub ahead of print.

    Letter, Reply:

    Reply to V. Fallet et al.

    • Homologous recombination deficiency predicts the response to platinum-based neoadjuvant chemotherapy in early-stage triple-negative breast cancer patients: a systematic review and meta-analysis.
    • Zhang L, Chen Y, Cheng MY, Zhuang X, Zou J, Wei D, Lin YY, Zhang Y, Wang K.
    • Ther Adv Med Oncol. 2022 May 7;14:17588359221096253. doi: 10.1177/17588359221096253.